GlassScriptPhysician profile
Abdul Ghani
NPI 1699711341
$3,421.58
in general payments reported to CMS, 2019-2025
23 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $563 · 2021: $532 · 2022: $971 · 2023: $260 · 2024: $497 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.26 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $686.50 | 2019-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $547.47 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $319.68 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.54 | 2020-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $264.67 | 2020-2023 | |
| Abbott Laboratories | $207.67 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $164.99 | 2020-2021 | |
| Corcept Therapeutics | $160.85 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $153.23 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $143.99 | 2021-2022 | |
| Pfizer INC. | $79.79 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $79.00 | 2020-2023 | |
| Emergent Biosolutions INC. | $56.96 | 2019 | |
| Grt US Holding, INC. | $53.75 | 2022 | |
| Insulet Corporation | $45.36 | 2021-2023 | Omnipod |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $39.09 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $31.85 | 2021 | |
| Amarin Pharma, INC. | $24.23 | 2020 | |
| Allergan, INC. | $19.31 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.92 | 2020 | |
| Nevro Corp. | $18.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.41 | 2021 | |
| Zealand Pharma US, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Ghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.